CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net loss	$ (366)	$ (1,426)
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition:
Depreciation and amortization	1,065	732
Amortization finance lease	37	32
Change on operating lease	5
Employee stock compensation expense	181	81
Provision for doubtful accounts	72
Unrealized foreign currency gains	9	18
Financing lease interest expense	69	67
Changes in operating assets and liabilities:
Accounts receivable	(634)	(1,013)
Inventories	(176)	61
Income tax accruals	33	97
Prepaid expenses and other assets	(231)	(774)
Accounts payable	435	479
Accrued expenses	(1,089)	597
Customer advances	2,242	2,501
Net cash provided by operating activities	1,652	1,452
Investing activities:
Capital expenditures	(1,474)	(2,165)
Cash paid in acquisition	0	(3,931)
Net cash used in investing activities	(1,474)	(6,096)
Financing activities:
Payments on finance lease liability	(108)	(104)
Payments of long-term debt	(712)	(250)
Payments of debt issuance costs	(40)	(110)
Payments on revolving line of credit	0	(10,531)
Borrowings on revolving line of credit	0	10,194
Borrowings on construction loan	0	1,183
Borrowings on capex line of credit	387	728
Proceeds from exercise of stock options	44
Borrowings on long-term loan	0	3,439
Net cash (used in) provided by financing activities	(429)	4,549
Net decrease in cash, cash equivalents, and restricted cash	(251)	(95)
Cash, cash equivalents, and restricted cash at beginning of period	1,406
Cash, cash equivalents, and restricted cash at end of period	1,155	511
Supplemental disclosure of cash flow information:
Cash paid for interest	256	270
Preclinical Research Services acquisition:
Assets acquired	0	6,442
Liabilities assumed	0	(1,378)
Common shares issued	0	(1,133)
Cash paid	$ 0	$ 3,931